Credit Suisse Group AG reaffirmed their buy rating on shares of Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) in a research note released on Tuesday morning. They currently have a $25.00 price objective on the stock.
Other analysts also recently issued reports about the company. Cantor Fitzgerald set a $23.00 price objective on Corvus Pharmaceuticals and gave the stock a buy rating in a report on Saturday, August 6th. Zacks Investment Research upgraded Corvus Pharmaceuticals from a hold rating to a buy rating and set a $14.00 price objective for the company in a report on Monday, June 20th. Finally, BTIG Research began coverage on Corvus Pharmaceuticals in a report on Thursday, June 2nd. They set a buy rating for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $21.60.
A number of hedge funds have recently made changes to their positions in the stock. FMR LLC increased its stake in shares of Corvus Pharmaceuticals by 5.3% in the second quarter. FMR LLC now owns 2,311,297 shares of the company’s stock valued at $32,959,000 after buying an additional 116,500 shares in the last quarter. Jennison Associates LLC increased its stake in shares of Corvus Pharmaceuticals by 22.9% in the second quarter. Jennison Associates LLC now owns 570,481 shares of the company’s stock valued at $8,067,000 after buying an additional 106,349 shares in the last quarter. BlackRock Advisors LLC increased its stake in shares of Corvus Pharmaceuticals by 437.2% in the second quarter. BlackRock Advisors LLC now owns 456,117 shares of the company’s stock valued at $6,504,000 after buying an additional 371,217 shares in the last quarter. Scopia Capital Management LP bought a new stake in shares of Corvus Pharmaceuticals during the first quarter valued at about $3,096,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Corvus Pharmaceuticals during the second quarter valued at about $2,497,000. Hedge funds and other institutional investors own 82.91% of the company’s stock.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of agents, which target the immune system to treat patients with cancer. The Company is developing drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells.
Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.